Aspartylphenylalanine
peptideDipeptide marker of altered proteolytic and inflammatory metabolism in acute coronary syndrome.
Pathway placement
Cascade stepPlaque inflammation
Confidencelow
RationaleDipeptide associated with ACS risk; may reflect altered proteolysis and inflammation.
Also acts inMyocardial injury
Druggability
Not assessed (no mapped human gene target).
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Plasma (EDTA; peptidase-labile — chilled + protease inhibitor)
Collection tube
K2-EDTA, chilled plastic (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
Competitive/sandwich immunoassay or LC-MS/MS
Reagent / substrate
Anti-peptide antibody; or isotope-labeled internal standard (MS)
Platform
Immunoassay / LC-MS/MS
Turnaround · availability
Send-out / research · Research-grade
Literature evidence(1)
- Nontargeted Metabolomics Revealed Novel Association Between Serum Metabolites and Incident Acute Coronary Syndrome: A Mendelian Randomization Study.Journal of the American Heart Association · 2023 · PMID 37382146 · doi